Posters
Clinical outcomes: a cost-effective sutureless scleral fixation technique without using fibrin glue
Poster Details
First Author: F.Akata TURKEY
Co Author(s): E. Yuksel E. Ozdemir N. Mammadova M. Ozmen I. Hepsen K. Bilgihan
Abstract Details
Purpose:
To define the sutureless scleral fixation technique of 3-piece foldable IOL without using fibrin-glue and evaluate the results.
Setting:
Department of Ophthalmology, Gazi University, Ankara, Turkey
Methods:
Retrospective single-surgeon case series of 7 patients who underwent SSF because of surgical aphakia or IOL subluxation were included. After conjunctival dissection, two limbus based scleral flaps (3 mm x 1.5 mm) were created, 180 degrees apart. Under scleral flaps, a pocket inside sclera was created with 27 gauge needle 1mm from the limbus. A 23-gauge needle was used to create sclerotomy 1 mm from the limbus under scleral flap. Haptics of subluxated / newly injected 3-piece IOL were externalized through the sclerotomies and tucked into scleral pockets. IOL haptics through the sclera and scleral flaps were sutured with 8/0vicryl.
Results:
The mean age was 57.1±29.3 years (13-83). All patients had at least 6-month follow-up, the mean follow-up was 16.8±7.9 month (6-26). There was significant improvement in UCVA (p= 0.000) and BCVA (p= 0.028). The mean degree of IOL tilt was 0.98±0.17°. Haptic exposure or slippage form the scleral pocket are not seen in any of the cases and long term IOL stabilization is achieved in all.
Conclusions:
Sutureless methods of scleral fixation become popular because of the long term suture knot–related complications such as suture erosion, suture breakage, endophthalmitis, Due to high cost of fibrin glue, we performed a sutureless scleral fixation technique without using fibrin glue. This technique seems to be a good option for the treatment of IOL subluxation and surgical aphakia with comparable clinical outcomes to sutured-scleral fixationand fibrin glue method. This technique is both cost effective and helps to avoid long term suture related complications.
Financial Disclosure:
NONE